Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Cancer

    • Home
    • Cancer
    • Page 139
Company Drug

Zai Lab’s Optune Approved by China’s NMPA, Offering New Hope for Glioblastoma Patients

Fineline Cube May 14, 2020

Zai Lab Ltd (NASDAQ: ZLAB), a biopharmaceutical company based in China, has received approval from...

Posts pagination

1 … 138 139

Recent updates

  • NMPA Releases 101st Batch of Generic Reference Drugs
  • Zenshine Pharma Files for Hong Kong IPO with $357M Valuation
  • Moderna Partners with Recordati on mRNA-3927 for Rare Propionic Acidemia
  • Illumina Completes $350M SomaLogic Acquisition to Expand Proteomics Portfolio
  • Microport EP Medtech’s EasyEcho ICE Catheter Wins NMPA Market Clearance
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

NMPA Releases 101st Batch of Generic Reference Drugs

Company Deals

Zenshine Pharma Files for Hong Kong IPO with $357M Valuation

Company Deals

Moderna Partners with Recordati on mRNA-3927 for Rare Propionic Acidemia

Company Deals

Illumina Completes $350M SomaLogic Acquisition to Expand Proteomics Portfolio

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.